ALECTOR INC (ALEC)

US0144421072 - Common Stock

6.06  -0.02 (-0.33%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ALECTOR INC

NASDAQ:ALEC (3/28/2024, 2:09:48 PM)

6.06

-0.02 (-0.33%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap580.25M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALEC Daily chart

Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 246 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegenerative diseases. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its clinical programs include AL001 (latozinemab), AL101, and AL002. In addition, the Company also focuses on preclinical and research programs in its pipeline for indications, including Alzheimer’s disease, Parkinson’s disease, and oncology. Its first product candidate, latozinemab, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients.

Company Info

ALECTOR INC

131 Oyster Point Blvd., Suite 600

South San Francisco CALIFORNIA 94080

P: 14152315660

CEO: Arnon Rosenthal

Employees: 246

Website: https://alector.com

ALEC News

News Image6 hours ago - Investor's Business DailyRace To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

News Image17 days ago - Market News VideoNotable Two Hundred Day Moving Average Cross - ALEC
News Image22 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!

News Imagea month ago - Alector, Inc.Alector to Participate in Upcoming Healthcare Conferences
News Imagea month ago - Alector, Inc.Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...

News Imagea month ago - Seeking AlphaAlector GAAP EPS of -$0.49 beats by $0.28, revenue of $15.2M beats by $6.36M (NASDAQ:ALEC)

Alector's Q4 earnings beat expectations with a higher revenue, and the company provides guidance for collaboration and expenses in 2024.

ALEC Twits

Here you can normally see the latest stock twits on ALEC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example